SONOMA PHARMACEUTICALS INC (SNOA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.33+0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SNOA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. As previously reported, on September 26, 2025, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which the Company may offer and sell, from time to time, through Ladenburg, as agent, shares of its common stock, $0.0001 par value per share. Sales of shares of common stock under the Agreement are made pursuant to the registration statement on Form S-3 (Fil…
Entry into a Material Definitive Agreement. On April 24, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc. (the “Underwriter”). Pursuant to the terms of the Underwriting Agreement, the Company agreed to issue and sell to the Underwriter an aggregate of 2,962,962 units, each unit consisting of one share of common stock, par value $0.0001 per share or, in lieu of common stock, if purchasing…
Entry into a Material Definitive Agreement. On April 8, 2026, we entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn ® technology-based products in the United States. The agreement is effective as of October 24, 2025 through March 2027, subject to up to two additional one-year terms upon mutual written agreement. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreeme…
Director — Dr. Jay Birnbaum: Dr. Jay Birnbaum retired from the Board of Directors and was succeeded by Ms. Vanessa Jacoby.
Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the…
The filing describes an annual equity grant to employees and directors, which is a routine administrative matter.
Executive Vice President and Chief Operating Officer — Bruce Thornton: Mr. Thornton was terminated for cause and will not receive any further salary or benefits.
Chief Operating Officer — Bruce Thornton: The Chief Operating Officer is retiring and the position will be eliminated.
Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the…
Entry into a Material Definitive Agreement. On September 26, 2025, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which the Company may offer and sell, from time to time, through Ladenburg, as agent, shares of its common stock, $0.0001 par value per share. Subject to the terms and conditions of the Agreement, Ladenburg will use commercially reasonable efforts consi…
Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the…
Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the…
Entry into a Material Definitive Agreement. As previously disclosed, effective January 29, 2025, we entered into a Master Supply Agreement (the “Master Supply Agreement”) with WellSpring Pharmaceutical Corporation (“WellSpring”) for the sale of Microcyn ® technology-based products to large retailers in the United States. The Master Supply Agreement is for an initial term of two years, subject to three automatic one-year renewal periods. On March 21, 2025, we entered into an Amendment No. 1 to…
Entry into a Material Definitive Agreement. Effective January 29, 2025, we entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of Microcyn ® technology-based products to large retailers in the United States. The agreement is for an initial term of two years, subject to three automatic one-year renewal periods. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a…
The filing describes the annual equity grant to employees and executive officers, including non-employee directors.
Termination of a Material Definitive Agreement. On March 26, 2021, we entered into an Exclusive Supply and Distribution Agreement with EMC Pharma, LLC (“EMC”). The Agreement gave EMC the exclusive right to sell and distribute our prescription dermatological and eye care products based on our Microcyn® technology in the United States. Pursuant to the Agreement, EMC was required to purchase certain minimum product quantities and pay a quarterly royalty to retain the exclusive rights. The agreem…
Entry into a Material Definitive Agreement. As previously reported, effective August 19, 2024, we entered into a distribution agreement (the “Agreement”) with Medline Industries, LP (“Medline”), for the marketing and distribution of our wound care products in the United States. The Agreement is for an initial term of five years, subject to automatic one-year renewal periods. On October 17, 2024, we entered into Amendment No. 1 to the Distribution Agreement (the “Amendment”), which allows Medl…
Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the…
Entry into a Material Definitive Agreement. Effective August 19, 2024, we entered into a distribution agreement with Medline Industries, LP, for the marketing and distribution of our wound care products. The agreement is for an initial term of five years, subject to automatic one-year renewal periods. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a redacted copy of which is filed herewith as Exhibit…
Regulation FD Disclosure. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are furnished hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial pe…
Regulation FD Disclosure. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are furnished hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial pe…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing…
Entry into a Material Definitive Agreement. As previously disclosed, on December 15, 2023, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) t…
Regulation FD Disclosure. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are furnished hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial pe…
Entry into a Material Definitive Agreement. Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union. The agreement is for an initial term of two years, subject to automatic renewal periods. These products combine the Company’s existing eye product Ocudox ® , which already has a Class IIB CE mark for…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.